NEW YORK (GenomeWeb) – Helomics has signed a contract to provide its tumor profiling products and services to preferred provider organization Prime Health Services.
Pittsburgh-based Helomics offers a suite of comprehensive tumor profiling products for live and fixed tumor cell assays, including the ChemoFx chemo response marker, which predicts whether a tumor will respond to standard chemotherapies. These products and services will now be available to more than 700,000 members of Prime Health's national organization.
"The combination of ChemoFx treatment selection markers, PCAP live tumor cell platform, and Helomics' complementary genomics and proteomics products provides physicians with treatment insights that allow for a truly personalized approach to treating each patient’s cancer," Helomics President and CEO Neil Campbell said in a statement.
Financial and other terms of the agreement were not disclosed.
One recently published 10-year study showed ChemoFx increased a patient's overall survival by 50 percent, the firm said in a statement. Another study showed that using ChemoFx to inform treatment decisions in ovarian cancer patients has the potential to be cost-effective in both platinum-sensitive and platinum-resistant patients.
Helomics was formerly known as Precision Therapeutics and changed its name in November 2014.